# BillionToOne, Inc.: overview BLLN · Nasdaq · CIK 2070849 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/blln.md) · [Financials](/companies/blln/financials.md) · [Filings](/companies/blln/filings.md) · [Insiders](/companies/blln/insiders.md) Latest reported revenue: [$109.4m](/filings/0002070849-26-000050.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0002070849-26-000050). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [38.4](/filings/0001628280-25-056321.md) | [45.1 d](/filings/0002070849-26-000017.md) | [59.0](/filings/0002070849-26-000031.md) | [66.6](/filings/0002070849-26-000050.md) | [83.5](/filings/0001628280-25-056321.md) | [96.1 d](/filings/0002070849-26-000017.md) | [108](/filings/0002070849-26-000031.md) | [109](/filings/0002070849-26-000050.md) | | Gross margin | % | [52.6%](/filings/0001628280-25-056321.md) | [57.1% d](/filings/0002070849-26-000017.md) | [64.4%](/filings/0002070849-26-000031.md) | [65.3%](/filings/0002070849-26-000050.md) | [69.9%](/filings/0001628280-25-056321.md) | [71.4% d](/filings/0002070849-26-000017.md) | [73.0%](/filings/0002070849-26-000031.md) | [70.5%](/filings/0002070849-26-000050.md) | | Operating margin | % | [(32.9%)](/filings/0001628280-25-056321.md) | [(25.9%) d](/filings/0002070849-26-000017.md) | [(3.9%)](/filings/0002070849-26-000031.md) | [(2.4%)](/filings/0002070849-26-000050.md) | [11.5%](/filings/0001628280-25-056321.md) | [10.8% d](/filings/0002070849-26-000017.md) | [16.5%](/filings/0002070849-26-000031.md) | [5.0%](/filings/0002070849-26-000050.md) | | Net margin | % | [(38.8%)](/filings/0001628280-25-056321.md) | [(25.5%) d](/filings/0002070849-26-000017.md) | [(6.8%)](/filings/0002070849-26-000031.md) | [(0.4%)](/filings/0002070849-26-000050.md) | [6.8%](/filings/0001628280-25-056321.md) | [6.2% d](/filings/0002070849-26-000017.md) | [16.6%](/filings/0002070849-26-000031.md) | [7.4%](/filings/0002070849-26-000050.md) | | Diluted EPS | $ per share | [(1.47)](/filings/0001628280-25-056321.md) | not reported | [(0.39)](/filings/0002070849-26-000031.md) | [(0.02)](/filings/0002070849-26-000050.md) | [0.10](/filings/0001628280-25-056321.md) | not reported | [0.34](/filings/0002070849-26-000031.md) | [0.15](/filings/0002070849-26-000050.md) | | Free cash flow | $m | not reported | [(10.5) d](/filings/0002070849-26-000017.md) | [0.3](/filings/0002070849-26-000031.md) | [(1.7) d](/filings/0002070849-26-000050.md) | [7.9 d](/filings/0001628280-25-056321.md) | [9.3 d](/filings/0002070849-26-000017.md) | [11.0](/filings/0002070849-26-000031.md) | [5.1 d](/filings/0002070849-26-000050.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [71.7](/filings/0002070849-26-000017.md) | [153](/filings/0002070849-26-000017.md) | [305](/filings/0002070849-26-000017.md) | | Gross margin | % | [24.1%](/filings/0002070849-26-000017.md) | [53.0%](/filings/0002070849-26-000017.md) | [68.3%](/filings/0002070849-26-000017.md) | | Operating margin | % | [(96.9%)](/filings/0002070849-26-000017.md) | [(30.9%)](/filings/0002070849-26-000017.md) | [5.3%](/filings/0002070849-26-000017.md) | | Net margin | % | [(115.3%)](/filings/0002070849-26-000017.md) | [(27.2%)](/filings/0002070849-26-000017.md) | [2.4%](/filings/0002070849-26-000017.md) | | Diluted EPS | $ per share | [(8.45)](/filings/0002070849-26-000017.md) | [(4.12)](/filings/0002070849-26-000017.md) | [0.14](/filings/0002070849-26-000017.md) | | Free cash flow | $m | [(59.8)](/filings/0002070849-26-000017.md) | [(46.8)](/filings/0002070849-26-000017.md) | [15.7](/filings/0002070849-26-000017.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/blln/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ADAMS STREET PARTNERS LLC](/funds/1193586.md) | 2026-06-30 | $205.3m | 1,711,430 | | Unchanged | | [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $108.2m | 901,420 | | Reduced −358,573 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $100.9m | 840,970 | | Added +689,757 | | [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $100.3m | 835,614 | | Added +429,102 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $95.9m | 799,468 | | Added +617,005 | | [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $91.7m | 764,215 | | Added +55,001 | | [BAMCO INC /NY/](/funds/1017918.md) | 2026-06-30 | $89.0m | 742,093 | | Added +608 | | [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $62.2m | 518,084 | | Added +148,446 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $51.0m | 425,032 | | New +425,032 | | [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $50.2m | 418,565 | | New +418,565 | ## Recent filings [All 168 filings](/companies/blln/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 16:42 ET | [10-Q](/filings/0002070849-26-000050.md) | Quarterly report, period 2026-06-30 | 0002070849-26-000050 | | 2026-08-05 | 16:25 ET | [8-K](/filings/0002070849-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002070849-26-000048 | | 2026-06-29 | 16:08 ET | [8-K](/filings/0002070849-26-000042.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0002070849-26-000042 | | 2026-06-16 | 16:57 ET | [8-K](/filings/0002070849-26-000040.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0002070849-26-000040 | | 2026-05-06 | 16:43 ET | [10-Q](/filings/0002070849-26-000031.md) | Quarterly report, period 2026-03-31 | 0002070849-26-000031 | | 2026-05-06 | 16:11 ET | [8-K](/filings/0002070849-26-000029.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002070849-26-000029 | | 2026-04-21 | 16:25 ET | [DEF 14A](/filings/0002070849-26-000024.md) | Proxy statement, period 2026-06-10 | 0002070849-26-000024 | | 2026-03-11 | 16:55 ET | [10-K](/filings/0002070849-26-000017.md) | Annual report, period 2025-12-31 | 0002070849-26-000017 | | 2026-03-04 | 16:07 ET | [8-K](/filings/0002070849-26-000013.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0002070849-26-000013 | | 2026-01-20 | 19:46 ET | [SCHEDULE 13D](/filings/0001104659-26-005176.md) | Ownership report, active investor | 0001104659-26-005176 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002070849-26-000017.md), filed Mar 11, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8b3bf57a-c514-4123-a999-581bc7a9463a) ## About the filer - CIK: 2070849 - Tickers: BLLN - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 18:55 ET. No prices; not investment advice.